Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6995-7004
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6995
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6995
Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization
Woo Sun Rou, Byung Seok Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Division of Gastroenterology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 301-721, South Korea
Author contributions: Lee BS contributed to the conception, design, analysis, and supervision of the study; Rou WS performed the research, designed the study, analyzed the data, and wrote the manuscript; Moon HS and Lee ES contributed to the analysis and discussion; Kim SH and Lee HY contributed to the discussion and review of the manuscript.
Correspondence to: Byung Seok Lee, Professor, Division of Gastroenterology, Department of Internal Medicine, Chungnam National University College of Medicine, 282 Munwha-ro, Jung-gu, Daejeon 301-721, South Korea. gie001@cnuh.co.kr
Telephone: +82-42-2807125 Fax: +82-42-2544553
Received: November 20, 2013
Revised: January 27, 2014
Accepted: March 7, 2014
Published online: June 14, 2014
Processing time: 207 Days and 18.8 Hours
Revised: January 27, 2014
Accepted: March 7, 2014
Published online: June 14, 2014
Processing time: 207 Days and 18.8 Hours
Core Tip
Core tip: We analyzed the risk factors for early local recurrence following transcatheter arterial chemoembolization (TACE) and investigated the treatment method and therapeutic results for local recurrence. This study showed that patients with early local recurrence had significantly lower survival rates and unfavorable treatment responses to repetitive TACE. Therefore, careful follow-up is believed to be necessary in patients exhibiting risk factors for early local recurrence, such as non-compact lipiodol uptake, large tumors, and an alpha-fetoprotein level > 20 ng/mL. Moreover, there was a small chance of a complete response after TACE, and considering other treatments or combining multiple treatments would therefore be advisable.